Our second blog post in our Type 2 Diabetes Prevention series is about the link between gestational...

Timely Diabetes Care Demands a New Approach to Testing
Half of all adults currently living with diabetes remain undiagnosed. Given the significant population health implications of missed or delayed detection, an immediate step-change is required in how we test for diabetes.
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Simplified testing. Increased patient throughput. Better outcomes.
Timely Diabetes Care Demands a New Approach to Testing
Half of all adults currently living with diabetes remain undiagnosed. Given the significant population health implications of missed or delayed detection, an immediate step-change is required in how we test for diabetes.
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Simplified testing. Increased patient throughput. Better outcomes.
Introducing innovative OGTT home testing platforms designed to support the timely and accurate detection of all types of diabetes.
Introducing innovative OGTT home testing platforms designed to support the timely and accurate detection of all types of diabetes.
Home Testing for Early Diabetes Detection
Digostics' home testing platforms ensure more patients can be easily tested, on time.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.
Home Testing for Early Diabetes Detection
Digostics' home testing platforms ensure more patients can be easily tested, on time.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results, and unparalleled opportunities for earlier clinical intervention.
100% focus on diabetes
Cutting-edge testing platforms
Pioneers of accurate home testing
Introduced the world's first home OGTT
Leaders in patient-centred design
Open architecture and system interoperability
100% focus on diabetes
Cutting-edge testing platforms
Pioneers of accurate home testing
Introduced the world's first home OGTT
Leaders in patient-centred design
Open architecture and system interoperability
"OGTTs are an important but inaccessible test. However, Digostics' OGTT home-testing approach could change this by making the detection of prediabetes, GDM and diabetes convenient and easy to perform."
Professor Stephen Colagiuri
"OGTTs are an important but inaccessible test. However, Digostics' OGTT home testing approach could change this by making the detection of prediabetes, GDM and diabetes convenient and easy to perform."
Professor Stephen Colagiuri
100% Focus on Diabetes
Digostics create and deliver class-leading test and service platforms that enable the early identification of diabetes through efficient screening of at-risk individuals.
With the support of leading clinical advisors and academic partners, we are proud to offer groundbreaking solutions that push the boundaries of what is achievable in diabetes detection.
100% Focus on Diabetes
We create and deliver class-leading test and service platforms that enable the early identification of diabetes through efficient screening of at-risk individuals.
With the support of leading clinical advisors and academic partners, we are proud to offer groundbreaking solutions that push the boundaries of what is achievable in diabetes detection.
Leaders in Remote Diabetes Testing
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
Leaders in Remote Diabetes Testing
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
Click to learn more about GTT@home
Unlocking the full population health potential of diabetes screening at home requires the elimination of all procedural complexities, allowing patients to complete their tests confidently without the need for clinical assistance.
With our deep expertise in human factors and by thorough extensive user testing and refinement, Digostics ensures that our diabetes home testing solutions are as convenient and effortless to use as they are accurate.
Unlocking the full population health potential of diabetes screening at home requires the elimination of all procedural complexities, allowing patients to complete their tests confidently without the need for clinical assistance.
With our deep expertise in human factors and by thorough extensive user testing and refinement, Digostics ensures that our diabetes home testing solutions are as convenient and effortless to use as they are accurate.
Download the Digostics Company Datasheet
Digostics' cutting-edge diagnostic platforms allow clinical researchers to access at speed and scale tests that were previously a major barrier to achieving breakthroughs.
We are adding new test and service elements to our platforms to empower researchers by easing patient recruitment, boosting compliance, reducing clinic visits and enriching datasets.
Digostics is a strong advocate of interoperability. That's why all our diabetes testing platforms are built with an open architecture and adhere to the HL7 FHIR standards.
Clinical users have the freedom to perform a range of tasks, from scheduling tests to analysing data, securely and conveniently within our software. Alternatively, they can draw on our API and productised integrations to undertake the same activity from within their preferred adjacent hospital systems.
Digostics is a strong advocate of interoperability. That's why all our diabetes testing platforms are built with an open architecture and adhere to the HL7 FHIR standards.
Clinical users have the freedom to perform a range of tasks, from scheduling tests to analysing data, securely and conveniently within our software. Alternatively, they can draw on our API and productised integrations to undertake the same activity from within their preferred adjacent hospital system.
Digostics' cutting-edge diagnostic platforms allow clinical researchers to access at speed and scale tests that were previously a major barrier to achieving breakthroughs.
We are adding new test and service elements to our platforms to empower researchers by easing patient recruitment, boosting compliance, reducing clinic visits and enriching datasets.
Click the button to register to download a datasheet providing Digostics company information and introducing our ground-breaking work in diabetes home testing.
Check out the latest posts from Insights, the Digostics blog.
Our second blog post in our Type 2 Diabetes Prevention series is about the link between gestational...
This week marks Type 2 Diabetes Prevention Week and as a contribution we want to shed light on five...
Gestational diabetes mellitus (GDM), like many health conditions, is diagnosed by an individual...